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CHAPTER I 
INTRODUCTION 
EPIDEMIOLOGY, GENETICS AND NATURAL HISTORY 
Psoriasis is a common chronic skin disease. The world-wide prevalen-
ce vanes and seems dependent on geographic and racial factors. A high 
prevalence of about 2.B% was found among the inhabitants of the Faroe 
Islands in contrast to very low percentages for Japanese Eskimos.1 
The disease is most common in Europe and the whole of North America; 
among American Indians, however, the disease is very rare.2 In Wes-
tern Europe the prevalence is about 2%. Most studies regarding the 
man-to-woman ratio, report no differences between the sexes.^»2 
Psoriasis is supposed to be a heriditary disease, varying in expres-
sion and depending on triggering factors (Table I). »^ Perhaps the 
most direct evidence for the genetic basis of psoriasis appears from 
twin studies. Farber et al reported a so-called pairwise concordance 
ratio (= number of pairs in which both partners have psoriasis out of 
the total number in the group) of 0.73 in the monozygotic group, and 
0.20 in the dizygotic group. Some factors seem to trigger psoria-
sis. Skin injury caused by operations, sunburn, venapunction or pres-
sure can induce psoriatic lesions in genetically predisposed people. 
This observation is known as the Koebner phenomenon. Guttäte psoriasis 
is reported to occur following streptococcal throat infections. Other 
infectious diseases, however, can affect the onset or the course of 
psoriasis as well. Psychogenic factors play an important role in 
psoriasis. Patients often experience an increase of the disease acti-
vity during or following 'periods of stress'. A warm, dry and sunny 
climate is described to be beneficial, as opposed to a foggy, cold 
climate.2 Some drugs like lithium,° Q-blocking agents and indome-
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thacin have been reported to induce psoriasis or to cause an exacerba-
tion in pre-existing psoriasis. 
triggering 
traumas 
infections 
stress 
climate 
drugs 
factorb 
hormonal changes 
metabolical changes 
Table I. Factors that can provoke psoriasis 
in genetically predisposed people. 
The onset and the course of psoriasis is unpredictable. The first 
signs of the disease can appear at any age. Psoriasis can be present 
at birth but onset at a high age is more frequent. Färber and Nail 
found a peak incidence in the third decade of life.? A second lower 
peak is described in the seventh decade. With respect to the course of 
psoriasis, it is impossible to say whether or not a certain patient 
will remain free from lesions after a period. Most patients, however, 
will need a life-long treatment. In general, one can state that the 
earlier the age of onset, the worse the prognosis, except in guttäte 
psoriasis, which has a better prognosis for children than for adults. 
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CUTANEOUS MANIFESTATIONS 
In psoriasis we can distinguish different skin manifestations. Chro-
nic stable plaque psoriasis is the most common form and is 
characterized by sharply defined erythemato-squamous plaques, varying 
in shape and size, covered with silverwhite scales which are most 
frequently localized on the extensor parts of the knees and elbows, 
the scalp and the sacral region (Fig la). 
In guttäte psoriasis, which is a less common erythemato-squamous 
form, multiple lesions of a diameter of 1 to 10 millimeters are 
scattered over the trunk and limbs (Fig 1b). 
Erythrodermic psoriasis is characterized by generalized erythema and 
scaling. Approximately 25л of the erythrodermas is caused by psoria­
sis. 
Less frequent is the generalized pustular psoriasis (von Zumbusch 
type). Sterile pustules appear on an erythematous skin (Fig 1c). This 
form is often accompanied by fever. Localized pustular forms can vary 
in shape, size and localisation. Pustular palmo-plantar psoriasis is 
restricted to the palms and soles (Fig le) and acrodermatitis continua 
of Hallopeau is a pustular manifestation localized on the fingers and 
toes (Fig Id). 
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Fig. la. chronic plaque psoriasis on the 
extensor site of the knee 
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Fig. Ib. guttäte psoriasis 
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Fig. 1c. generalised pustular psoriasis 
fSprr Λ 
Fig. Id. acrodermatitis continua of Hallopeau 
Fig. Ie. pustulosis of the palms and soles 
EXTRACUTANEOUS MANIFESTATIONS 
Many authors have described an association between psoriasis and 
artnntis. Arthritis was observed more often in psoriatic patients 
than in a control group.8 Nevertheless exact data about the preva-
lence of this so-called 'psoriasis arthropatica' are not available. 
Psoriasis arthropatica is characterized by a mono or asymmetrical 
oligo-arthropathy, with involvement of the distal or proximal int'er-
phalangeal joints of the toes or fingers, the hips, the cervical or 
the sacroiliacal joints and a negative Waaler-Rose and Rheuma test. 
Most radiological changes are similar to those in rheumatoid arthritis 
but some features are characteristic of psoriatic arthritis. 
Of the psoriatic patients, 10-55% show abnormalities of the nails, 
like pitting, horizontal ridging, distal onycholysis, subungual kera-
tosis and the 'oil-spot phenomenon' (Fig 2a,b,c). 
Associations with internal diseases have been reported. They inclu-
de: Crohns disease, ulcerative colitis, dermatogenic enteropathy, 
liver impairment, diabetes, occlusive vascular disease, amyloidosis 
and gout. Although an association with psoriasis has been claimed, 
literature is conflicting and statistical evaluation is not convin-
cing.' 
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HISTOPATHOLOGY 
The micromorphology of the fully developed psoriatic lesion shows 
acanthosis, absence of the stratum granulosum, lengthening of the rete 
ridges with thickening of the lower parts, squirting papillae with a 
small suprapapillar epidermis with parakeratosis and hyperkeratosis 
(Fig 3a). In the basal cell-layer and suprabasal layer, an increase of 
the mitotic index can be seen and in the dermis, oedema and dilatated 
capillaries are observed, which are surrounded by an infiltrate of 
lymphocytes, histiocytes and some polymorphonuclear leukocytes (PMN), 
the latter especially during exacerbations (Fig 3b). 
In the epidermal infiltrate, the PMN are most prominent. They migra-
te through the squirting papillae and form spongiform micropustules of 
Kogoi. Accumulation of PMN in the stratum corneum are called micro-
abscesses of Munro. The extent of the infiltrate and the presence of 
microabscesses in the epidermis depends on the disease activity. 
All pustular forms of psoriasis are histologically characterized by 
the formation of macropustules containing large amounts of PMN inter-
mingled with a spongiform network of degenerated epidermal cells.1" 
•^ Fig. 2. Nail changes in psoriasis. 
(a) subungual keratosis 
(b) pitting 
(c) oil-spot phenomenon and 
distal onycholysis 
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Fig. 3. Histopathology of a chronic plaque lesion, 
(a) overview showing the typical shape of 
the rete ridges and focal parakeratosis 
(b) penetration of polymorphonuclear leukocytes 
into the epidermis 
TREATMENTS 
The classical treatments for psoriasis are based on empirical obser­
vations. 
Topical corticosteroids, perhaps the most advocated treatment, are 
effective. Short-term side-effects are minimal, but long-term treat­
ment includes the possibility of atrophy of the skin. Severe relapses 
may occur following discontinuation of this therapy. 
Dithranol is an effective and safe topical therapy; a careful dosage 
management is essential, however, it is a therapy suited for in­
patient departments or day-care centres. 
Photo(chemo)therapy is often used in psoriasis. Ultraviolet В radia­
tion, or ultraviolet A radiation following the ingestion or topical 
application of 8-methoxypsoralen have a potent antipsonatic ef­
fect. ^  The longterm risk of both treatments is the development of 
basal and squamous cell carcinoma. ' 
Systemic treatment with the cytotoxic agent methotrexate is extreme­
ly effective in psoriasis. Nevertheless, side-effects, such as hepa-
toxicity and haematopoietic suppression indicate that sustained super­
vision of the patient is necessary. Exact protocols are available.^ 
Etretinate is a systemic agent, very efficacious in erythrodermic 
and pustular psoriasis. In chronic plaque psoriasis combined regimes 
of etretinate with topical therapies are effective. Patients using 
etretinate should visit the dermatologist at regular intervals, for 
dosage adjustments based on clinical effectivity and side-effects. 
At present new antipsonatic therapies, based on the growing insight 
in the pathogenesis of psoriasis, are in the phase of clinical trials. 
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The immunosuppressant cyclosporin is being investigated in several 
centres.14 Drugs interfering with eicosanoid metabolism is another 
new issue. Benoxaprofen, a 5-lipoxygenase inhibitor proved to be 
effective in psoriasis.15 Dietary manipulation with eicosapentanoic 
acid has been reported to have a mildly antipsonatic effect.'° 
PATHOGENESIS 
Several metabolic pathways may be involved in the pathogenesis of 
psoriasis. Indeed a variety of changes has been described. Some of the 
major observations on this subject, reported over the past 15 years, 
will be summarized: 
The epidermis 
Extensive research has been done on the role of the keratinocyte. 
Glycogen accumulation and hyperproliferation are the most prominent 
characteristics of the epidermis of the psoriatic lesion. First 
messenger signals (adrenaline, Prostaglandine E2, histamine) can acti-
vate a plasmamembrane bound enzyme, adenylcylase, which causes an ele-
vation of the intracellular level of cyclic adenosine monophosphate 
(second messenger). This system, which plays an important role in the 
homeostasis, inhibits epidermal proliferation and induces glycogen 
brakedown. Voorhees et al. described a disregulation of this system in 
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psoriasis.17 in the epidermis of the psoriatic lesion a defective 
responsiveness of adenylcyclase for adrenalin stimulation has been 
shown.18 in this respect it is of interest that ß-blocking agents 
aggravate psoriasis. 
More recently calmodulin has been proposed as a candidate for 
epidermal disregulation in psoriasis.1' Indeed increased 
intracellular levels of calmodulin have been shown in psoriatic 
lesions. The increase proved to be specific for psoriasis and 
seborrhoic dermatitis.20 
Polyamines are absolute requirements for growth in microorganisms. 
Increased levels of polyamines and increased activity of the enzyme 
ornithine decarboxylase (the rate limiting step of their biosynthesis) 
have been observed in lesionai skin of psoriatic patients. ' The 
polyamine antagonist methylglyoxal partially improves psoriasis.21 
Proteases and antiproteases are important regulators of epidermal 
growth and increased levels of proteolytic enzymes have been demon-
strated in lesionai psoriatic skin. Fräki demonstrated an increased 
activity of the epidermal plasminogen activator in psoriatic epider-
mis, which seems independent of circulating factors, as these abnorma-
lities persisted after transplantation of the lesions to 'nude' 
22 mice. ' 
Electron microscope studies of lesionai psoriatic skin revealed a 
decreased intercellular adhesion between keratinocytes, which may 
result in a reduction of contact-growth-inhibition.^' 
More recently Bjerke et al. showed retгоvirus-like particles in the 
psoriatic plaque which may be responsible for abnormal epidermal 
growth.''* 
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The dermis 
In lesionai skin the capillaries are dilatated and angioneogenesis 
has been shown. Electronmicroscopic studies demonstrated that vascular 
changes are 'a conditio sine qua non' for the development of the pso-
riatic lesion.25,26 j^g fibroblasts, derived from clinically invol-
ved and uninvolved skin, showed an increased outgrowth in tissue cul-
ture and an increased production of macromolecules.27,28 ¡t
 Was sug-
gested that increased epidermal and dermal proliferative activity are 
the consequences of the same trigger, possibly a vascular stimulus. 
Hormonal changes 
Several hormonal changes have been reported in psoriatic patients. 
Holzman et al. reported an increased synthesis of dehydroepiandroste-
rone. " Van de Kerkhof observed increased plasma aldosterone le-
vels·50 and Weber et al. identified increased levels of somatotropic 
hormone. -^  
T-cell mediated immune response 
A specific T-cell mediated immune response has been suggested as the 
cause of psoriasis." Abnormalities have been reported in circula-
ting blood lymphocytes. Disease activity, however, seems to be of 
crucial importance in the expression of the abnormalities. In chronic 
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stable plaque psoriasis parameters in peripheral blood lymphocytes are 
essentially normal.33 л-^ Langerhans cell is said to be abnormal in 
psoriasis and might play an important role in the presentation of 
antigens in the T-cell mediated immune response34. 
Intraepidermal accumulation of polymorphonuclear leukocytes 
The intraepidermal penetration of polymorphonuclear leukocytes (PMN) 
into the epidermis resulting in the formation of spongiform pustules 
of Kogoi and microabscesses of Munro, is a dominating feature in early 
psoriatic lesions. In PMN of psoriatic patients with actively sprea­
ding lesions increased activities of neutral proteinases have been 
reported.35 i
n
 patients with chronic stable plaque psoriasis, how­
ever, PMN functions are essentially normal.33,35 
In the clinically involved skin several chemotactic factors have 
been identified: C5a36, anionic neutrophil activating peptide3° 
and arachidonic acid metabolites.37 in the clinically uninvolved 
skin the activity of phospholipase A2 is increased.38,39 jhig enzyme 
is the rate limiting step in the arachidonic acid cascade. Arachidonic 
acid is metabolized via the cyclo-oxygenase pathway in prostaglandins 
and via the lipoxygenase route in leukotnenes (Fig 4). Prostaglan­
dins, leukotnene C4 and leukotnene D4 are vasoactive. The lipoxyge­
nase products leukotnene B4 (LTB4) and 12-hydroxyeicosatetraenoic 
acid (12-HETE) are potent chemoattractants. In the clinically uninvol­
ved skin of psoriatic patients an increased formation rate of LTB4 has 
been demonstrated.^ Recently it has been shown that topical appli-
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esteri fled, unreleased arachidonic acid 
phospho]ipase A2 12 hydroxyeicosatetraenoic acid 
12 lipoxygenase t 
arachidonic acid 12 hydroxyperoxyeicosatetraenoic acid 
cyclo-oxyqenase 
- Indometacin 
5 lipoxygenase 
benoxyprofen 
5 hydroxyeicosatetraenoic acid 
11 hydroxyperoxyeicosatetrdennoic acid 5 hydroxyperoxyeicosatetraennoic acid 
I I 
prostaglandin"! leukotnene A4 
/ \ 
leukotnene B4 leukotnene C4 
Ipukotnene D4 
leukotnene E4 
F i g . 4 . The a r a c h i d o n i c a c i d cascade. 
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cation of LTB4 results in intraepidermal accumulation of PMN4', 
followed by an accumulation of mononuclear cells, vasodilatation and 
increased epidermal proliferation.42 
The hypothesis that the production of LTB4 and its biological 
effects are crucial in the pathogenesis of psoriasis is borne out by 
the following clinical observations: 
- The 5-lipoxygenase inhibitor benoxaprofen reduces the production of 
LTB4 and 12-НЕЛЕ and causes an improvement of psoriasis." 
- Indomethacin causes a depletion of cyclo-oxygenase products and an 
overflow of lipoxygenase products, resulting in an exacerbation of 
psoriasis.4·' 
- Eicosapentanoic acid antagonizes LTB4 and improves psoriasis. ° 
AIM AND OUTLINE OF THE THESIS 
This thesis attempts to provide insight into the role of the leuko-
tnene B^iLTB^-induced accumulation of polymorphonuclear leukocytes 
(PMN) in the initiation, maintenance and therapeutically induced 
regression of the psoriatic lesion. 
The general methodology for inducing PMN accumulation in skin by 
topical application of LTB4 and the method for quantification of PMN 
using the marker enzyme elastase, will be described in chapter II. 
The LTB^-induced PMN accumulation in clinically uninvolved skin of 
psoriatic patients, compared to the response in healthy controls will 
be described in chapter III. The modulation of LTB^-induced micropus-
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tule formation by methotrexate and etretinate will be dealt with in 
chapters IV and V. In order to get better insight into the role of 
this phenomenon in the maintenance of the psoriatic lesion, we studied 
the spontaneous and LTB4-induced PMN accumulation in chronic plaque 
lesions (chapters VI and VII). Chapter VIII will deal with the PMN 
accumulation in various zones of annular pustular psoriasis. 
Elastase inhibitors might be relevant to the penetration of PMN into 
the epidermis. A preliminary characterization of an elastase 
inhibitor, characteristic of lesionai psoriatic skin will be presented 
in chapter IX. 
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CHAPTER II 
ELA5TASE, A MARKER FOR POLYMORPHONUCLEAR LEUKOCYTES 
IN SKIN INFILTRATES 
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SUMMARY 
The enzyme elastase (EC 3.4.21.37) has proved to be a convenient and 
extremely sensitive marker for the quantification of polymorphonuclear 
leukocytes (PMN) in cutaneous infiltrates. Fluorometnc assay using 
the synthetic substrate MeOsuc-Ala-Ala-Pro-Val-N-methylcoumann 
permitted the measurement of this enzyme in as few as 5 cells and was 
linear to about 1000 cells per sample. The mean activity of lysates of 
human blood-derived PMN was 0.57 ± 0.08 pmol of 7-amino-4-methylcou-
mann released per hour per PMN. Extracts of normal human skin 
contained no measurable elastase activity but resulted in a slight 
inhibition of the PMN enzyme (mean 12%). 
Application to the in vivo situation has been demonstrated by the 
use of leukotnene B4 as chemotactic agent. A reproducible PMN infil-
trate was found at a dose of 2 ng, well below the threshold for the 
appearance of microabscesses. 
Infiltration by PMN is a characteristic feature of many skin 
lesions. Since the density of the infiltrate provides an indication of 
the local intensity of the disease process, a method for the quantifi-
cation of these cells would clearly be of value. It has already been 
shown that myeloperoxidase can be used as a specific marker enzyme for 
this purpose, but unfortunately the sensitivity of the technique 
described was not sufficient to permit its routine application to 
human biopsy material.' 
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We have recently explored the use of an alternative enzyme, elastase 
(EC 3.4.21.37). Like myeloperoxidase, elastase is very specific for 
the polymorphonuclear leukocyte and is present in large quantities in 
the granules.2,3 ¡t has the additional advantage, however, that a 
simple and exceedingly sensitive fluorometric assay is available.4 
Here we present data to show that elastase is indeed a convenient and 
sensitive marker for blood PMN and describe a pilot study to demon-
strate that it can be used to quantify infiltrating PMN in small biop-
sies of human skin. 
MATERIALS AND METHODS 
Materials 
The substrate, MeOSuc-Ala-Ala-Pro-Val-N-Methylcoumann, was obtained 
from Bachern, Bubendorf, Switzerland. Leukotriene B4 (LTB4) was 
puchased from Paesel GmbH, Frankfurt. All other chemicals were of the 
highest grade available and were obtained from E. Merck, Darmstadt, 
Germany. 
Blood was obtained by venepuncture of healthy paid volunteers, and 
polymorphonuclear leukocytes isolated by standard procedures.' The 
washed cells ( > 905» PMN) were lysed by somcation in a buffer con-
taining 0.3?ί cetnmide, 0.1M tris and 1 M NaCI (pH 8.5) at a concen­
tration of 10^ cells/ml. All dilutions were made in this same buffer. 
- 29 -
Elastase assay 
Elastase was determined by the fluorescence of 7-amino-4-methyl-
coumann released from the substrate MeOSuc-Ala-Ala-Pro-Val-N-Methyl-
coumann.^ A 10 mM stock solution of the substrate in dimethyl-sulpho-
xide was diluted to 250 μΜ with cetnmide buffer (above) on the day of 
use. The reaction was initiated by the addition of 20 μί of the dilu­
ted substrate to 20 μί aliquots of cell or skin extracts in 4 ml plas­
tic tubes. A blank (20 μί substrate plus 20 μί cetnmide buffer) was 
always included. After incubating the covered tubes at 370C for Ih, 
the reaction was stopped by cooling in ice and diluting to 1 ml with 
carbonate-bicarbonate buffer (0.1 M, pH 10.5). Fluorescence was measu­
red at Л
е х
 = 375 nm, Л en, = 440 nm using the Perkin-Elmer LS 5 spectro-
fluorometer. Enzyme activity was calculated by reference to a standard 
solution of 7-amino-4-methylcoumarin in carbonate-bicarbonate buffer 
(100 pmol per ml). 
Preliminary experiments verified that the reaction was linear with 
time for at least 90 mins under the conditions described. 
Quantification of cutaneous infiltrates 
In order to verify that elastase can be used as a marker for cuta­
neous PMN in vivo, we took advantage of the fact that topical applica­
tion of LTB4 to the skin induces a rapid and specific infiltrate of 
these cells.6,7,θ 
Three volunteers were selected with no sign or history of skin 
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disease. Aliquots of 1, 2, 5, 10 and 20 ng LTB4
 l n ethanol were 
applied to test-sites on the back as described previously.8 After 24 
hours, 'shave' biopsies were taken freehand using a razorblade in 
conjunction with a metal guard. The biopsies (approximately 3 mm dia­
meter and 0.2 mm thick) were thoroughly rinsed in phosphate-buffered 
saline, dried between filter-papers and weighed (average 1-2 mg). They 
were homogenized at 2 mg/ml in cetnmide buffer using an all-glass 
Potter-type grinder, and the homogenate centnfuged (3000 rpm, 10 
mins) to yield a clear supernatant. Aliquots of 20 μΐ of this extract 
(diluted 1:10 with cetrimide buffer where necessary) were assayed for 
elastase as described previously. 
Prior consent of the Medical Ethics Committee of this University was 
obtained for this experiment. 
RESULTS 
Investigations in vitro 
The relationship between the fluorescence intensity and cell number 
for a lysate of blood-derived PMN is illustrated in Figure 1 (upper 
line). It is seen that as few as 5 cells per assay are sufficient for 
a reliable elastase measurement; this number yields a fluorescence of 
about double the blank value. The mean activity of 3 separate prepara­
tions (± SEM) was 0.57 ± 0.08 pmol/hour/PMN. 
Possible inhibition of PMN elastase activity by skin was studied by 
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the assay of appropriate dilutions of the same PMN preparation in the 
presence of an extract of human skin (final concentration 2 mg/ml). 
The results are shown in Fig. 1 (lower line). It is seen that there is 
indeed a slight inhibition (in this case IISí) which is independent of 
cell number. The mean inhibition produced by 5 different samples of 
normal human skin (all at 2 mg/ml) was 122Í SEM ± 4Й. 
Fluorescence 
1000 
1 0 0 
I I I I 
5 10 20 40 100 200 400 1000 
No of PMN 
Fig. 1. Log-log plot of fluorescence intensity (arbitrary 
units) versus number of PMN per assay. 
Correlation coefficient for both lines 
better than 0.99995. 
o-o PMN only 
α-D PMN in the presence of 2 mg/ml skin extract. 
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Quantification of cutaneous infiltrates 
No erythema, oedema or pustulation was visible 24 hours after the 
application of LTB4 in doses up to 20 ης per tost site. 
Elastase activity was determined on each biopsy, and the density of 
infiltrating PMN calculated using the value of 0.57 pmol/hour PMN 
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Fig. 2. Quantification of PMN density in skin biopsies 
taken 24 hours after different doses of LTB4. 
Each point is the mean ± SEM of three experiments. 
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(above). The results (mean ± SEM) are illustrated in Fig. 2. It is 
seen that a response could be measured in all 3 subjects down to 2 ng 
LTB4; especially at the highest dose, however, there was a rather wide 
variation in the density of the infiltrate between the different 
subjects. No elastase activity was found in untreated skin, control 
sites treated with ethanol only or at a dose of 1 ng LTB4. 
DISCUSSION 
Using figures for the specific activity of purified leukocyte elas­
tase against MeOSuc-Ala-Ala-Pro-Val-N-methylcoumann quoted by Castil­
lo et al.^ and correcting for the different substrate concentrations, 
the elastase activity reported here corresponds to about 0.6 pg enzyme 
protein per PMN. This compares well with the value of about 0.5 pg per 
PMN found by these workers. It may also be noted that the same group 
estimate the ultimate sensitivity of the assay to be about 330 pg per 
ml elastase protein; for a 20 μΐ sample this would correspond to 13 
PMN again of the same order as in the present study. Thus it is clear 
that the fluorometnc determination of elastase as marker for PMN is 
about a thousand times more sensitive than the spectrophotometnc 
assay of myeloperoxidase, which requires a minimum of 10000 cells per 
assay.1 This improvement in sensitivity permits the quantification of 
minimal infiltrates in very small biopsy specimens. 
Elastase seems to be a rather specific marker enzyme for polymor­
phonuclear cells. The only other blood-derived cell possessing this 
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enzyme is the monocyte, which contains about 5л of the activity found 
in the PMN.' The properties of the monocyte type elastase are diffe­
rent from the PMN type elastase. Quantification of elastase in the 
eosinophil has not been reported, so care is required in the interpre­
tation of data from infiltrates containing appreciable numbers of this 
cell type. Regarding the recovery of the extraction technique, it has 
been established that the elastase activity which is released follow­
ing stimulation of the intact cell is 90-1005S of that found after 
detergent lyses.10 The relatively small degree of inhibition of PMN 
elastase by skin extracts which we report here (averaging 12%) is 
presumably because the sulphated glycosaminoglycans, which are potent 
inhibitors of this enzyme^, are complexed by cetrimide.^ it may be 
noted that replacing cetrimide by Triton X-100 as detergent, although 
yielding the same elastase activity for blood-derived PMN, resulted in 
almost complete inhibition of the enzyme by skin extracts (data not 
shown). Nevertheless, it is clearly advisable to correct for endoge­
nous inhibitors by the inclusion of a standardized PMN extract as 
'internal standard' in parallel assays. 
The application of this approach to the in vivo situation has been 
demonstrated using LTB4 as chemotactic agent. It is apparent that PMN 
can be quantified well below the level at which histological evidence 
of microabscesses has been reported.β 
The actual density of the infiltrate at the highest dose of LTB4 (54 
PMN per μg skin) is rather close to the figure of 85.5 PMN per μq skin 
reported in experimental staphylococcal infection of rat skin.^ 
There remains the possibility, however, that in chronic lesions much 
of the elastase may be released into the surrounding tissue and lost 
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by diffusion or inactivation; the magnitude of this problem remains to 
be evaluated. 
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SUMMARY 
The 'in situ' infiltration of polymorphonuclear leukocytes following 
the topical application of leukotriene B4 to the clinically uninvolved 
skin of psoriatic patients and the skin of normal controls has been 
quantified using elastase as a marker enzyme. The magnitude of this 
response in the psoriatic patients proved to be significantly dimi­
nished compared with the response in the controls. The time course of 
the response was similar in both groups, a maximum elastase activity 
being seen about 18h after application of the LTB4. 
We have recently described a method for the quantification of poly­
morphonuclear leukocytes (PMN) in small 'shave' biopsies of human skin 
using the marker enzyme elastase.1 This technique is specific and 
exceedingly sensitive. In this previous paper we also reported pre­
liminary data to show that the marker enzyme could be used to evaluate 
the response of PMN to topically applied leukotriene B4 (ίΤΒή).^ 
In this paper we extend our previous study and characterize the time 
course of the response. We have also investigated the behaviour of 
clinically uninvolved skin of psoriatic patients in an attempt to 
throw further light on the reduced sensitivity of the psoriatic skin 
to LTB4 already reported by Wong et al.' 
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PATIENTS AND METHODS 
Seven psoriatic patients and seven controls participated in this 
study. The patients were aged 21-39 years and had had no treatment for 
at least one month. Their lesions were limited to a few stable pla-
ques. The healthy controls were aged 21-37 years and had no history 
nor signs of psoriasis. Approval of the Medical Ethics Committee was 
obtained prior to the experiments being conducted. 
Aliquots of 10 ng LTB4 (Paesal GmbH, Frankfurt, F.R.G.) were applied 
to test sites on the backs of patients and controls. In the patients 
applications were at least 20 cm from a psoriatic lesion. The method 
of application has been described in detail elsewhere.^ In all 
patients and controls biopsies were taken free-hand, using a razor 
blade in conjunction with a metal guard, at six different time inter-
vals following LTB4 application: 0,6,12,18,24 and 36 hours. 
Processing of biopsies and analytical procedures were as described 
previously.^ In brief, the biopsies were washed thoroughly in phos-
phate-buffered saline, homogenized in cetrimide buffer and centri-
fuged. Elastase activity was determined in 20 «1 aliquots of the 
supernatant (diluted where necessary) using the fluorogenic substrate 
MeOSuc-Ala-Ala-Pro-Val-N-methylcoumarin. Correction was made for endo-
genous inhibition by the skin extracts, and the density of infiltra-
ting PMN calculated using the value of 0.57 pmol 7-amino-4-methylcou-
marin released per h per PMN.^ Evaluation of differences between the 
patient group and the control group for any individual time point was 
carried out using the Wilcoxon ranking test. 
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RESULTS 
A clinical response to the application of LTB4 was seen only in one 
patient. This patient showed a slight erythema 36 hours following LTB4 
application. Both in controls and in psoriatic patients all test sites 
healed without complications. 
P M N perpg skin 
Θ 0
Ί 
0 6 12 18 2U 30 36 
hours 
Fig. 1. PMN per pq skin at different time intervals 
following the application of 10 ng LTB4. 
Means ± SEM of 7 experiments. 
• — · controls 
о — о psoriatic patients 
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Quantification of PMN per цд skin following LT84 application is 
shown in Figure 1. Immediately following the application no PMN were 
seen. At 6 hours following LTB4 application, an average of 18.2 PMN/ug 
skin (normals) and 3.4 PMN/^g skin (psoriatic patients) were present. 
The controls reached a maximum after 1Θ hours (average 66.9 PШ/μq 
skin) and a maximum response, averaging 22.9 PHN/μq skin, was seen in 
the patients. The overall response in the psoriatic patients was 
significantly lower compared with the response in controls. The 
differences between patients and controls reached statistical signifi­
cance at 6 hours (0.025 < P< 0.05) and 18 hours (P < 0.01) following 
LTB4 application. 
Inhibition of a standard elastase preparation by skin extracts (all 
specimens) was 6 ± Ιίϊ (mean ± SEM). In this respect no significant 
difference was seen between psoriatic patients and controls. The 
inhibition did not increase during the 36 hours following LTB4 appli­
cation. 
DISCUSSION 
After the topical application of 10 ng LTB4 we observed a clinical 
response in only one of the 14 subjects, whereas Wong et air reported 
an erythema in most subjects even using 5 ng LTB4. This might be due 
to a different localization of the LTB4 application sites.* Another 
possibility is the use of Finn chambers by the London group for 6 h 
following LTB4 application, in contrast to the non-occlusive system 
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employed in our experiments. 
The infiltrate analysis following LTB*, application using the elas-
tase assay leads to the same conclusion as reached by Wong et al': The 
intraepidermal accumulation of PMN in the uninvolved skin of psoriatic 
patients is decreased in comparison to the response in normal con-
trols. The time curve (Fig. 1) indicates that this decrease is not the 
result of an acceleration or retardation of the infiltration process. 
Elastase is believed to be of importance in facilitating the pene-
tration of PMN into tissues.5 In skin an elastase inhibitor is pre-
sent^, and it seemed possible that the reduced infiltration in the 
psoriatic skin, as well as the 'tolerance' following repeated applica-
tions of LTB4, could be the consequences of increased levels of this 
inhibitor. However, the level of inhibition (averaging 6% in the 
present series) did not increase significantly during the 36h after 
LTB4 application, nor was there any difference between the degree of 
inhibition in the psoriatic group compared with the controls. 
We agree with Wong et al^ that the production of LTB4 by the epi-
dermis is probably not of primary pathogenetic significance as no 
psoriatic lesion has been seen following the application of this sub-
stance. However, it still might be one of the obligatory prerequi-
sites. In this respect it is of interest that methotrexate at thera-
peutic doses inhibits the LTB4-induced intraepidermal accumulation of 
PMN.* 
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SUMMARY 
The leukotnene B4 (LTB4)-induced intraepidermal accumulation of 
polymorphonuclear leukocytes (PMN) was quantified using the elastase-
assay in psoriatic patients receiving methotrexate and in untreated 
psoriatic patients. 
Methotrexate in therapeutic dosages inhibited PMN infiltration in 6 
patients who had improved considerably on treatment with this drug, a 
gradual recovery being seen during the days that no methotrexate was 
taken. Two patients were in relapse, despite methotrexate treatment 
and both failed to show any change in LTB^-induced accumulation of 
polymorphonuclear leukocytes. 
According to the common belief, methotrexate (MTX) works through an 
inhibition of DNA synthesis. Its efficacy in pustular psoriasis has 
led several investigators to study the influence on the in vitro Che-
motaxis of PMN, which proved to be inhibited by this drugs. 1)2,3 in 
a preliminary study we showed that the LTB^-induced intraepidermal 
microabscess formation was substantially inhibited in 3 patients using 
MTX, indicating that the in vivo Chemotaxis is also modulated by the 
drug at least at the time that it is being taken.* 
In the present study we have measured the intraepidermal accumula-
tion of PMN following the application of LTB4 to the clinically unin-
volved skin of psoriatic patients, using the enzyme elastase, a highly 
sensitive and specific marker for PMN. We compared the response of 
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MTX-treated and untreated psoriatic patients. The duration of the 
effect of the in vivo Chemotaxis was assessed and correlated with the 
clinical effectivity. 
PATIENTS AND METHODS 
Patients 
The MTX-treated group consisted of В patients (aged 35-61 years) 
with chronic plaque psoriasis. Before initiating MTX treatment, more 
than ЗОй of the body surface was involved in all cases. The patients 
had been treated for 3 months to 5 years with a weekly oral schedule 
of 3 divided doses at 12-hour intervals.' The total weekly dose in 
these patients was 7.5 mg or 10 mg. At the time of investigation the 
disease in six patients was quiescent, with less than b% of the body 
surface affected. Two patients were in relapse, with an involvement of 
more than 10?ó of body surface, despite MTX treatment. 
Ten psoriatic patients (aged 24-60 years), who had been untreated 
for at least one months, were selected as controls. Their skin lesions 
were limited to less than 55í of the body surface. 
Prior consent of the Medical Ethics Committee of Nijmegen University 
was obtained for this experiment. 
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LTBu application and quantification of PMN 
Aliquots of 10 ng LTB4 were applied to the clinically uninvolved 
skin of the backs of all subjects.4,6 in ^ e MTX-group the first 
LTB4 application was performed 2 h after the second dose of MTX. The 
second and third LTB4 applications were performed 3 and 6 days after 
PMN per^ug skin 
60 
MTX 
Fig. 1a. PMN per |Ug skin 24 h after the application of 10 ng 
LTB4 in psoriatic patients at different intervals 
following MTX treatment. The shaded area represents 
mean ± SEM of untreated patients. 
The response in 6 patients with quiescent psoriasis. 
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the third dose of MTX (Fig. 1). In the untreated psoriatic patients a 
single application of 10 ng LTB4 was carried out. Twenty-four hours 
after the LTB4 application, biopsies were taken freehand using a razor 
blade in conjunction with a metal guard. The biopsies (approximately 3 
mm diameter and 0.2 mm thick) were processed for elastase measurement 
as described previously.^ 
Briefly, biopsies were washed in phosphate buffered saline, homoge­
nized in cetrimide buffer and centrifuged. Elastase activity was 
determined in 20 μΐ aliquots by measuring the fluorescence of 7-amino-
4-methylcoumarin released from the substrate MeOSuc-Ala-Ala-Pro-Val-
N-methylcoumarin, and the number of PMN per μg skin calculated as des­
cribed previously.' 
RESULTS 
The LTB4-induced accumulation of PMN in the six patients whose 
psoriasis was quiescent at the time of investigation is shown in 
Figure 1a. The mean response (± SEM) after the first application was 
47 ± 175» of the PMN accumulation observed following the third applica­
tion. The response in the middle of the week was inhibited by 27 ± 
IOS. The PMN accumulation following the first application was signifi­
cantly lower than the response after the third application (p < 0.05 
Wilcoxon rank test for paired data). The response in the six patients 
with quiescent disease after the first application was significantly 
lower than the response in the untreated patients (p < 0.05 Wilcoxon 
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rank test). 
The patients with unstable psoriasis despite of MTX treatment, did 
not show any inhibition of LTB4-induced, intraepidermal accumulation 
of PMN (Fig. 1b). 
PMN per^ ug skin 
Fig. lb. PMN per fiq skin 24 h after the application of 10 ng 
LTB4 in psoriatic patients at different intervals 
following MTX treatment. The shaded area represents 
mean ± SEM of untreated patients. 
The response in 2 patients with unstable psoriasis. 
α = patient 1 ; о = patient 2 
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DISCUSSION 
In early and active psoriatic lesions the intraepidermal accumula­
tion of PMN is a classical feature.8 Lipoxygenase products with a 
potent chemotactic activity such as LTB4 and 12-hydroxy-5,8,10,14-
eicosatetraenoic acid (12-HETE) have been demonstrated in the lesionai 
skin of psoriatic patients.9 In clinically uninvolved skin the increa­
sed rate of formation of LTB4IO has been found to be balanced by a 
decreased responsiveness to LTB4 applied topically.^»^ д decreased 
responsiveness to LTB4 has also been seen following repeated applica­
tions of this substance to healthy skin, indicating that local habi­
tuation processes exist.^ It follows that the penetration of the PMN 
into the epidermis during the development of the psoriatic lesion must 
be subject to cutaneous homeostatic control, and that the in vitro 
Chemotaxis of PMN does not give sufficiently information regarding the 
situation in vivo. We have shown here that, using the dermis and 
epidermis as a natural 'diffusion chamber', MTX inhibits PMN Chemota­
xis. This inhibition correlates with the clinical efficacy of MTX. The 
inhibition of in vivo Chemotaxis recovered gradually during the MTX-
free days of a weekly intermittent dose schedule. 
It is of interest that those MTX-treated patients with a quiescent 
state of their psoriasis showed a clear inhibition of PMN Chemotaxis, 
whereas those who did not respond well clinically, showed no inhibi­
tion. This implies that in vivo Chemotaxis must be closely linked to 
the target of MTX antipsoriatic activity. The clinical efficacy of the 
oral weekly schedules is well established, compared to the low-dosed 
daily schedules, the antipsoriatic effect is comparable whereas the 
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toxicity is very much lower. The most likely target for the antipso-
riatic action of MTX is a process which is affected by the drug on the 
days it is taken. The modulation of PMN Chemotaxis by MTX was found to 
follow the clinically effective dose schedule. 
We conclude that the PMN Chemotaxis is of relevance to the anti-
psoriatic action of MTX. Further studies are needed to elucidate the 
molecular mechanism involved. 
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SUMMARY 
The effect of etretinate on the intraepidermal accumulation of poly-
morphonuclear leukocytes following epicutaneous application of leuko-
triene B4 was studied in 5 psoriatic patients. Polymorphonuclear leu-
kocytes were quantified using the marker enzyme elastase. An inverse 
relationship was found between the dosage of etretinate and the number 
of infiltrated polymorphonuclear leukocytes. 
The inflammatory eicosanoid leukotriene B4 (LTB4) is a potent chemo-
tactic substance for polymorphonuclear leukocytes and its presence in 
the psoriatic lesion has been established.^>' In the clinically un-
involved skin of psoriatic patients an increased rate of formation of 
LTB4 has been reported. Epicutaneous application of LTB4 on normal 
human skin has been shown to produce microabcscesses of PMN within the 
epidermis.*»' 
In early or active psoriatic lesions the intraepidermal accumulation 
of polymorphonuclear leukocytes (PMN) 19 a characteristic histological 
feature.6»' 
Etretinate is an efficient treatment of psoriasis, especially in the 
pustular variants.8 Dubertret et al' reported that etretinate 
treatment at relatively high dosages (1 mg/kg/day) in normal volun-
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teers resulted in a decreased migration of PMN from the blood stream 
into skin chambers filled with autologous serum as chemoattractant. 
In the present study we investigated the effect of low doses of 
etretinate on the LTB4-induced intraepidermal accumulation of PMN. 
This interaction was studied by measuring the intraepidermal accumula­
tion of PMN following topical application of LTB4 on the clinically 
uninvolved skin of psoriatic patients treated with etretinate. The in­
filtrating PMN were quantified using the marker enzyme elastase.^ 
PATIENTS AND METHODS 
Five patients participated in this study. Patients details are lis­
ted in Table I. Three had chronic stable plaque psoriasis and the 
other two patients had persistent pustulosis of the palms and soles. 
patienb 
no 
1 
2 
3 
4 
5 
ех 
F 
F 
F 
F 
M 
age 
44 
54 
60 
47 
53 
body wpight 
(kg) 
70 
75 
100 
62 
70 
duration of 
psoriasis 
(years) 
6 
В 
9 
2 
10 
type of psoriasis 
chronic plaque 
psoriasis end 
palmo plantar 
pustulosis 
palmo plantar 
pustulOBiq 
chronic plague 
psoriasis 
pelmo plantar 
pustulosis 
chronic plaque 
psoriasis 
S body 
surface 
involved 
5 
< 5 
15 
< 5 
10 
duration of etre­
tinate therapy 
(montha) 
12 
1 
5 
1 
1 
Table I Details of patients taking part in the study. 
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Following the first LTB4 application the etretinate dosage was 
changed in all of the patients; in three patients the dosage was 
increased to enhance clinical effectiveness, in one patient the dosage 
was decreased because of severe cheilitis and rhinitis and in another 
patient etretinate was discontinued because of substantial hair loss. 
A second LTB4 application was made 3 weeks after changing the dosage 
of etretinate. Details on dosages are shown in Figure 1. At the time 
of the second LTB4 application the extent of skin lesions in each 
patient was the same as 3 weeks earlier. 
Aliquote of 10 ng LTB4 were applied to the clinically uninvolved 
skin of the backs of all patients as described previously.*»' Twen-
ty-four hours after LTB4 application a biopsy was taken freehanded 
using a razor blade in conjunction with a metal guard. The specimens 
were processed for elastase measurements as described by Lammers et 
al.''" Briefly, the biopsies were washed thoroughly in phosphate 
buffered saline, weighed, homogenized in cetnmide buffer and centn-
fuged. Elastase activity was measured in the supernatant fractions 
using the fluorogenic substrate MeOSuc-Ala-Ala-Pro-Val-N-methylcouma-
n n and the number of PMN per ^g skin was calculated from the fluores-
cence intensity. 
RESULTS 
The intraepidermal accumulation of PMN following LTB4 applications 
is shown in Figure 1. It can be seen that a decrease in the dosage of 
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etretinate resulted in an increased PMN accumulation, whereas an 
increase in the dosage of etretinate was accompanied by a decreased 
PMN accumulation. The inverse relationship between dosages of etreti­
nate and PMN accumulation is statistically significant (P < 0.02; Wil-
coxon matched-pairs signed-ranks test). 
PMN//jg skin 
80 
τ — ι — r " - v — ι — ι — ι — ι — г 
20 ДО 60 80 100 
Etretinate (mg) 
Fig. 1. Intraepidermal accumulation of PMN 24h after the 
epicutaneous application of 10 ng LTB4 in 5 pso­
riatic patients treated with different consecu­
tive dosages of etretinate. The arrows indicate 
an increase or decrease in the dosage. 
- 61 -
DISCUSSION 
The intraepidermal accumulation of PMN following LTB4 application 
varied considerably between patients treated with etretinate (Figure 
1). The mean response in untreated psoriatic patients (± SEM) was 27.7 
* 5.6.^ >12 No significant difference could be shown between the 
responses in etretinate treated patients and untreated patients. How­
ever, comparing PMN accumulations at different etretinate dosages in 
individual patients, a negative correlation with the dosage of etreti­
nate was evident. As can be seen in Figure 1 the dosage of etretinate 
at which a lower apparent threshold for LTB4-induced PMN accumulation 
was reached varied considerably from patient to patient. At a clinical 
level this is in accordance with the large inter-individual variabili­
ty in the minimal effective dosage of etretinate. 
The effect of etretinate on the LTB^-induced PMN accumulation is 
compatible with the dramatic effectiveness of the drug in the pustular 
manifestations of psoriasis.β The effect of etretinate on the in 
vitro Chemotaxis is not clear; some authors showed no significant 
changes" and others reported a significantly reduced chemotactic 
response in the presence of etretinate.1* Ellis et al^' suggested 
that etretinate might reduce the Chemotaxis of PMN by enhancing pro­
perties of psoriatic serum. Such a working mechanism could explain the 
discrepancy between some in vitro studies and the in vivo work. 
Now it has been shown that both etretinate and methotrexate^»^ 
inhibit the LTB4-induced accumulation of PMN in the epidermis at the­
rapeutical dosages. This strongly supports the hypothesis that the 
LTBipinduced PMN accumulation is not merely an epiphenomenon in the 
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pathogenesis of psoriasis but might provide a target for antipsoriatic 
therapies. 
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ABSTRACT 
The intraepidermal penetration of polymorphonuclear leukocytes is an 
early event in the pathogenesis of psoriasis. In the present study we 
quantified these cells in biopsies from lesionai epidermis of chronic 
stable plaque psoriasis. In this phase intraepidermal penetration of 
polymorphonuclear leukocytes was shown in 41% of the lesions. The 
micropustules of Kogoj were seen in 10% of the lesions. Pronounced 
parakeratosis was associated with the presence of polymorphonuclear 
leukocytes. Microabscesses of Munro were located exclusively within 
areas of parakeratosis. 
The absence of polymorphonuclear leukocytes in the majority of skin 
biopsies from chronic stable plaque psoriasis is compatible with the 
cyclic pattern of the migration of these cells into the skin. 
Intraepidermal penetration of polymorphonuclear leukocytes (PMN 
exocytosis) is reputed to be a classical feature of the psoriatic 
lesion.1 In the early phase of the lesion this phenomenon dominates 
the histological picture. In the established lesion the situation is 
less clear. According to some authors PMN invasion is one of the 
essential hall-marks.2»3 However, others^t^ state that PMN accumu-
lation in the epidermis is less impressive in this later phase. 
Fig. 1. Typical histologic appearance of intraepidermal • 
accumulation of PMN. 
(a) Micropustule of Kogoj 
(b) Sporadic intraepidermal PMN 
(c) Microabscess of Munro 
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As far as we know quantification of PMN infiltration in the epider­
mis of chronic stable plaque psoriasis has not been published. A quan­
titative histological study of chronic stable plaque psoriasis is the 
subject of this report. 
PATIENTS AND METHODS 
Seventeen patients with chronic stable plaque psoriasis participated 
in this study. All patients had been without any treatment for at 
least one month. The lesions were in a quiescent state without exuda­
tion. In total 29 lesions were studied. Biopsies of approximately 3 mm 
diameter and 0.4 mm thickness were taken free handed from the central 
areas using a razor blade in conjunction with a metal guard. The biop­
sies were processed for paraffin sectioning (6 μπι thickness) and Η 4 E 
staining using standard procedures. Intraepidermal PMN accumulations 
were studied in 20 fields of 1 mm diameter. 
Microabscesses 
(Munro) 
10/29 
Micropustules 
(Koqoj) 
3/29 
Sporadic accumulation 
2/29 
Table I. The occurrence of PMN in the epidermis 
of the psoriatic lesion 
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RESULTS 
The infiltration of PMN occurred as micropustules of Kogoj with 
their characteristic spongiform appearance (Fig. 1a), as microabsces-
ses of Munro (Fig. 1c) and as sporadic accumulations (Fig. 1b). Table 
I overviews the frequency of these intraepidermal infiltrations. In 17 
out of 29 lesions no PMN were seen. 
0-5 6-10 >11 
M icroabscesses / field 
Fig. 2. The relation between the number of microabscesses 
per unit surface area and parakeratosis density. 
Parakeratosis 
• mild 
• pronounced 
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In most biopsies parakeratosis was patchy. Munro microabscesses 
occurred only within parakeratotic areas. No PMN were seen in areas of 
orthokeratosis. The correlation between the density of parakeratosis 
(estimated as mild or pronounced) and the presence of microabscesses 
is shown in Figure 2. 
DISCUSSION 
In chronic stable plaque psoriasis intraepidermal PMN were seen in 
41й of the biopsies. The spongiform pustule of Kogoj, according to 
Lever and Schaumburg-Lever^ the characteristic hall-mark of psoriasis, 
could be observed only in 10% of the biopsies. The situation in early 
psoriasis is different. Chowaniec et al^ studied prepinpoint psoriatic 
papules and they observed abundant PMN in the inflammatory infiltrate 
in 7BÄ and sporadic accumulation of PMN into the epidermis was seen in 
91ÜÓ of the lesions. Burks and Montgomery' estimated the intraepidermal 
penetration of PMN in 'active' psoriasis, characterized by a history 
of rapidly developing lesions, prominent erythema and exudation. They 
found numerous and relatively large microabscesses. Gordon and 
Johnson° have also quantified intraepidermal PMN in active psoria-
sis: microabscesses were seen in 755ó and sporadic penetration of PMN 
into the epidermis was seen in 95Й of the lesions. 
The topography of the lesions in patients who are in a state of exa­
cerbation is not uniform. In spreading lesions, the penetration of 
leukocytes into the epidermis is localized in the margin zone and in 
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active sites it is scattered over the more central area of the 
lesion.' As to the topography of the lesions in chronic stable plaque 
psoriasis we can not make any definite conclusion by taking only one 
small biopsy specimen of 3 mm diameter from the central portion of 
each psoriatic plaque. However, in our series PMN were seen only in a 
minority of the biopsy specimens, indicating that the 'hot spots' of 
PMN accumulation are much more thinly diasiminated over the chronic 
stable lesions. 
The sparcity of PMN accumulation in the epidermis of chronic stable 
plaque psoriasis is in striking contrast to the consistent increase in 
parameters for epidermal cell cycle kinetics.^0 At a first glance it 
is tempting to conclude that the maintenance of the chronic lesion is 
thus independent from PMN infiltration. However, if we assume that the 
migration of PMN into the psoriatic lesion occurs in a cyclic pattern, 
the epidermal hyperproliferation could well be the consequence of 
preceding PMN accumulations. Evidence for this possibility is provided 
by the induction of microabscesses in the clinically uninvolved skin 
after the topical application of leukotriene B4 which is followed by 
epidermal hyperproliferation persisting up to 72 h after complete 
disappearance of PMN.^ 
In the present series we extended the observations of Cox^2 regar-
ding the relation between microabscesses of Munro and parakeratosis. 
This topographic and quantitative correlation could be substantiated 
not only in active psoriasis but also in the chronic stable plaque 
phase. It is likely that parakeratosis is secondary to PMN infiltra-
tion. In early psoriasis parakeratosis is relatively inconspicious 
compared to PMN exocytosis° and in general spongiform pustules are 
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covered by an orthokeratotic stratum corneum. 
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SUMMARY 
The intraepidermal accumulation of polymorphonuclear leukocytes fol­
lowing the epicutaneous application of leukotriene B4 (LTB4) was 
studied in lesionai and clinically uninvolved skin of 5 patients with 
chronic stable plaque psoriasis. The lesions were found to be wholly 
unresponsive to LTB4» doses of 100 ng failing to produce either micro-
pustules or sporadic migration of polymorphonuclear leukocytes into 
the epidermis. This phenomenon was sharply localized, the response 
immediately adjacent to the lesion being identical to that in more 
distant uninvolved skin. We speculated that both the reduced response 
to LTB4 in the psoriatic patient and also the tolerance seen after 
repeated applications of LTB4 result from the induction of a P450-
linked hydroxylase. 
In early and active psoriatic lesions the intraepidermal accumula­
tion of polymorphonuclear leukocytes (PMN) is a common feature. As the 
lesions mature this characteristic tends to become less conspicious 
despite the presence of several potent chemotactic factors.Ь' 
In order to investigate this discrepancy we studied the penetration 
of PMN into the epidermis of the chronic psoriatic lesion following 
the epicutaneous application of leukotriene B4 (LTB4). We also asses­
sed the penetration of PMN in response to LTB4 just outside the visi-
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ble edge of the lesion to find out whether the sharp clinical demarca­
tion is reflected at the level of PMN Chemotaxis. 
PATIENTS AND METHODS 
Five patients (2 males and 3 females, aged 20-63 years) suffering 
from chronic stable plaque psoriasis participated in this study. The 
duration of their disease varied from 16 to 4B years. The extent of 
the lesions ranged from 5 to 70% of the body surface. For this study 
lesions with mild to moderate scaling were selected. The patients 
received no systemic medication. Topical therapy was discontinued for 
2 weeks prior to the experiment. 
Aliquots of 100 ng LTB4 (Paesel GmbH, Frankfurt, Germany) in 10 μΐ 
ethanol were applied topically to the skin surface. Application sites 
were confined to an area of 5.5 mm diameter by using glass cylinders 
while the ethanol was evaporated under a stream of nitrogen. Test 
sites were marked and covered with impermeable dressings ('Silver 
patch', van der Bend, Groningen, The Netherlands). Previous investiga­
tions have revealed that topical application of 100 ng LTB4 to normal 
skin results in profuse intraepidermal accumulation of PMN.-'»* LTB4 
was applied to one lesion in each patient, close to the periphery of 
the lesion, and to the clinically uninvolved skin immediately adja­
cent to the lesion and 1 cm and 20 cm from the edge of the lesion. 
After 24 hours biopsies were taken freehand, using a razor blade in 
conjunction with a metal guard, from these test areas and also from 
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lesionai skin close to the periphery of the lesion, without LT84 pre­
treatment. Biopsies were processed for paraffin sectioning and haema-
totoxylin and eosin staining according to standard procedures. 
In 20 fields of 1 mm diameter, intraepidermal accumulation of PMN was 
recorded as follows: 
(i) sporadic penetration of PMN. 
(ii) aggregates of PMN within a spongelike network formed by degene­
rated and thinned epidermal cells ('micropustules of Ko-
goj'). 5 
(iii) accumulations of pyknotic PMN within the stratum corneum 
('microabscesses of Munro').-' 
(iv) aggregates of PMN without spongiform epidermis ('LTB4 induced 
micropustules'). 
SITE 
Lesion 
Lesion 
Adjacent to lesion 
1 cm from lesion 
20 cm from lesion 
Pretreatment 
with LTB4 
-
+ 
+ 
+ 
+ 
Microabscesses 
of Munro 
3 
2 
0 
0 
0 
MicropustuJ 
οΓ Koqoj 
1 
0 
0 
0 
Π 
es 
Sporadic 
intraepi­
dermal PMN 
LTB4-induced 
micropustules 
D 
0 
5 
5 
5 
Table I. Summary of histological data from 5 patients with 
chronic stable plaque psoriasis. 
The number of patients with positive findings is 
indicated. 
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RESULTS 
The micromorphology of a typical LTB^-induced micropustule is shown 
in Fig. 1, It can be seen that such a pustule lacks the spongiform 
appearance of a micropustule of Kogoj; furthermore, no parakeratosis 
was ever observed in conjunction with these experimental pustules. 
Occurrence of the different forms of intraepidermal accumulation of 
PMN in the 5 patients with chronic stable plaque psoriasis is summari­
zed in Table I. 
Fig. 1. LTB^-induced micropustule (original χ 200), 
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In lesionai skin, no LTB^-induced micropustules were seen in any 
patient. Immediately outside the lesion, at 1 cm and 20 cm distance 
from the lesion the responses were generally similar with pronounced 
micropustule formation occuring at all sites. Kogoj micropustules 
and/or Munro microabscesses were seen in some patients and these were 
restricted to lesionai skin. Sporadic penetration of PMN into the epi-
dermis was seen in one psoriatic lesion following LTB4 application and 
without pretreatment. 
DISCUSSION 
It has already been established that the clinically uninvolved skin 
of the psoriatic patient shows a somewhat diminished response to 
LTB4.6»7 Here we report the new and striking observation that the 
psoriatic lesion appears to be totally unresponsive to this mediator; 
doses of 100 ng failing to induce either micropustules or sporadic 
penetration of PMN into the epidermis. Further, we have shown that the 
area of unresponsiveness is sharply demarcated; the 'chemotactic boun-
dary' coinciding with the edge of the overt clinical changes. 
The percutaneous absorption of drugs in the psoriatic lesion is 
greatly enhanced due to the lack of integrity of the stratum cor-
neum. 8 Therefore the bioavailability of topical LTB4 should, if 
anything, be greater than in normal skin. However, a markedly thicke-
ned stratum corneum might not allow full percutaneous penetration of 
LTB4. Therefore patients with extremely hyperkeratotic plaques were 
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not included in this study. 
Three situations may now be compared. Firstly, repeated application 
of LTB4 to the skin of healthy individuals results in a locally dimi-
nished responsiveness.1 Secondly, the clinically uninvolved skin of 
patients with chronic plaque psoriasis, in which there seems to be a 
moderately increased LTB4 synthesis,' also shows a reduced sensitivity 
to topical LTB4 applications.6>7 Finally, in the lesion itself, 
characterized by a massive overproduction of arachidomc acid metabo-
lites including LTB^.^ we have now shown that the response to topi-
cal LTB4 is wholly abolished. It is clear that in all situations there 
13 a reciprocal relationship between the concentration of LTB4 to 
which the skin has been exposed and its sensitivity to experimental 
application of this mediator. 
In a general sense, this observation clearly reflects a shift in 
cutaneous homeostasis which may be seen as an attempt to stabilize the 
psoriatic process. The mechanism is still obscure. However, we know 
that LTB4 is degraded via a cytochrome P^g-linked oxidation,^ and 
it is also well-established that enzymes of this pathway are highly 
inducible. Following stimulation of skin in organ culture with benzan-
tracene, an enhanced inducibility of the cytochrome P450 dependent 
enzyme arylhydrocarbon hydroxylase has been shown in psoriatic epider-
mis as compared to normal epidermis.^ We may speculate, therefore, 
that the tolerance to LTB4 in the situations described above is the 
consequence of an elevated cutaneous P450-linked hydroxylase resul-
ting in accelerated breakdown. Further work is needed to test this 
hypothesis. 
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ABSTRACT 
A case of annular pustular psoriasis is described. The annular zone 
of the lesion provides a model for studying the dynamics of intraepi-
dermal accumulation of polymorphonuclear leukocytes in psoriasis. 
It could be shown that the unstimulated accumulation of polymorpho-
nuclear leukocytes was limited to the clinically involved skin. The 
appearance of polymorphonuclear leukocytes proved to be associated 
with acanthosis. The micropustule formation following topical applica-
tion of leukotnene B4 was markedly decreased in lesionai, pre-lesio-
nal and post-lesional skin, compared to the response in the clinically 
uninvolved skin of patients with chronic plaque psoriasis. 
Although leukotnene B4 might have an initiating role in the intra-
epidermal accumulation of polymorphonuclear leukocytes other factors 
are a conditio sine qua non for the peripheral spreading of the lesion 
in annular pustular psoriasis. 
The intraepidermal accumulation of polymorphonuclear leukocytes 
(PMN) is a characteristic histopathological hallmark of psoriasis.^ 
Several chemoattractive substances are of relevance in this respect. 
Leukotnene B4 (LTB4) is a highly potent chemoattractant and its 
presence has been demonstrated in the psoriatic lesion.2 In the 
clinically uninvolved skin of psoriatics the formation rate of LTB4 
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has been claimed to be increased.' 
Epicutaneous application of LTB4 results in the intraepidermal accu­
mulation of PMN.4>5 This approach provides the possibility to mea­
sure the chemotactic response of PMN to LTB4 using the dermis and epi­
dermis as a 'natural diffusion chamber'. 
The annular type of pustular psoriasis (APP) is a rare condition 
characterized by waves of pustulation on an erythematous background, 
spreading over the body by centrifugal expansion and central healing 
in the course of hours to days.° This manifestation offers a clini­
cal model 'par excellence' for studying the dynamics of PMN discharge 
in psoriasis. 
In the different zones of evolution and involution of the lesion we 
studied the histopathological picture. In order to find out whether 
facilitation or inhibition of the intraepidermal accumulation of PMN 
occurs we evaluated the LTB4-induced micropustule formation in the 
different zones of the lesion. For comparison the LTB4-induced micro-
pustule formation was evaluated in θ patients with chronic stable 
plaque psoriasis. 
CASE REPORT 
A 71-year-old Caucasian woman visited our department with annular 
pustular psoriasis (APP) and a seronegative arthropathy. During the 
last 16 years the patient has had episodes of annular pustular lesions 
with fever and general discomfort. These episodes occured several 
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times a year. 
The lesions consisted of annular zones with erythema and pustules, 
which were spreading by centrifugal expansion in the course of days. 
Centrally the lesions were clinically normal apart from a colerette 
scale. Figure 1 shows such a lesion. 
Several therapies for APP have been prescribed, including methotre-
xate, PUVA therapy, occasionally systemic corticosteroids and during 
the last years etretinate. Etretinate had been given in dosages be-
tween 25 and 75 mg per day with a variable clinical response. The 
arthropathy was treated with non-steroidal antiinflammatory drugs. 
Fig. 1. The clinical picture of annular pustular psoriasis. 
The different zones for the histological studies 
are indicated. 
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MATERIALS AND METHODS 
During an acute relapse a typical lesion was selected for the expe­
riment (Figure 1). In total 6 different zones were defined (Table 1). 
Aliquots of 100 ης LTB4 (Paesel GmbH, Frankfurt) in 10 μΐ ethanol were 
applied topically on the skin surface of zones 1, 5 and 6 as described 
previously.4,5 in brief, LTB4 was confined within an area of 5.5 mm 
diameter with the aid of glass cylinders while the ethanol was evapo­
rated under a stream of nitrogen. The test areas were marked with 
eosin. During 24 hours the application sites were covered with imper­
meable dressings ('Silverpatch', van der Bend, Groningen, The Nether­
lands). Within the lesionai skin (zone 5) LTB4 was applied on a test 
area with minimal scaling and without crusting in order to avoid the 
possibility of a decreased bioavailability in this test area. Follo­
wing an application period of 24 hours biopsies were taken from the 
LTB4 treated areas and from untreated sites in zones 1, 2, 3, 4, 5, 
Clinically 
Clinically 
Peripheral 
Pustules 
Paracentral 
Clinically 
normal 
normal 
skin, 
skin, 
erythema 
erythema and 
healed centre 
at 
adj 
CO 
20 cm 
acent 
lerett 
distance 
to 
e 
from 
the lesion 
the lesion 
Table I. Zones in annular pustular psoriasis. 
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and 6. Biopsies were taken free handed, using a razor blade in con­
junction with a metal guard. In the same way biopsies were taken from 
the clinically uninvolved skin of 8 patients with chronic stable pla­
que psoriasis following the application of 100 ng LTB4. Biopsies were 
processed for paraffin sectioning and H and E stainings were carried 
out. In 20 fields of 1 mm diameter of each biopsy PMN accumulation was 
studied. 
RESULTS 
Following the applications of LTB4 no erythema, oedema or pustula-
tion was seen. The histopathological picture of untreated sites in APP 
Fig. 2. The histology in zones 1 - 6 of a lesion of annular 
pustular psoriasis. Calibration bars equale 80 μη. 
Zone 1 No significant abnormalities 
Zone 2 essentially normal epidermis with 
perivascular infiltrate of mono­
nuclear cells 
Zone 3 acanthotic epidermis and penetrating 
polymorphonuclear leukocytes; pen-
vascular infiltrate, composed of poly­
morphonuclear leukocytes and mono­
nuclear cells 
Zone 4 and 5 Intraepidermal absces formation by 
polymorphonuclear leukocytes, epider­
mal acanthosis and hypergranulosis 
Zone 6 Slight acanthosis, no dermal abnorma­
lities 
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Fig. 3. High power photomicrographs of infiltrate in the peripheral 
zones of the lesions. Calibration bars equale 25 ^ m. 
(a) zone 2, perivascular infiltrate of mononuclear cells. 
(b) zone 3, acanthotic and spongiotic epidermis, 
penetration of polymorphonuclear leukocytes. 
(c) zone 3, mixed infiltrate of mononuclear cells and polymorpho­
nuclear leukocytes. 
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are shown in figure 2 and 3. The photomicrographs are an accurate 
representation of the features seen in 20 fields of each biopsy stu­
died. In zone 1 the histological picture was essentially normal. In 
zone 2 a perivascular infiltrate of mononuclear cells was seen; the 
epidermis was essentially normal. In zone 3 a mixed infiltrate of 
mononuclear cells and PMN was seen. The appearance of PMN was accompa­
nied by epidermal acanthosis; in 12 of the 20 fields of 1 mm diameter 
PMN penetrated into the dermis. In zone 4 massive intracorneal accumu­
lations of PMN were seen with epidermal acanthosis and hypergranulo-
sis. Zone 5 showed a similar picture; PMN were degenerated to a large 
Fig. 4. The typical histological picture, 24 hours follow­
ing the application of 100 ng LTB4. Calibration bars 
equale 120 μπ\. 
(a) centre of a lesion in annular pustular psoriasis, 
showing sporadic accumulation of polymorphonuclear 
leukocytes. 
(b) clinically uninvolved skin of chronic plaque 
psoriasis; a typical example, showing pronounced 
invasion of polymorphonuclear leukocytes. 
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extent. In zone 6 the histological picture was normal, apart from a 
slight acanthosis. 
The intraepidermal accumulation of PMN following LTB4 application 
consisted of sporadic migration and some small sized micropustules in 
zone 6 (Figure 4a). In zone 1 and 5 there was no LTB4 induced micro-
absces at all. The responses in the clinically uninvolved skin of the 
8 patients with chronic stable plaque psoriasis showed a pronounced 
PMN invasion (Figure 4b). 
DISCUSSION 
In this case of APP the unstimulated intraepidermal accumulation of 
PMN coincided with the zone of clinical involvement. The appearance of 
PMN was accompanied by epidermal acanthosis. In a previous study in 
APP the percentage of epidermal cells in S phase has been measured, 
using flowcytometry.7 The authors showed that epidermal prolifera-
tion was normal just outside the annular zone of pustulation, yealded 
markedly increased levels in the area of clinical involvement and 
remained elevated in the clinically normal skin of the centre. So in 
APP the appearance of PMN in the epidermis and epidermal hyperprolife-
ration show the same dynamics. This suggests a common metabolic path-
way for the initiation of both processes. In this respect it is of 
interest that at different levels in the molecular biology of cuta-
neous homeostasis epidermal growth control and the production of che-
motactic factors are linked. It has been shown that LTB4 and 12-hydro-
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xyeicosatetraenoic acid are potent stimulators of epidermal growth and 
possess powerfull chemotactic properties on PMN.8>9,10 Alternati­
vely, it has been suggested that the phosphoinositol cycle enhances 
epidermal growth via stimulation of proteinkinase С and the production 
of inflammatory eicosanoids.11 
In this patient with APP the intraepidermal accumulation of PMN 
following LTB4 application was profoundly decreased in all zones 
including the clinically uninvolved skin at a large distance from any 
lesion. Even a relatively high dose of LTB4 had no effect, whereas 
this dose in the clinically uninvolved skin of chronic plaque psoria­
sis provoked medium to large sized PMN accumulations. This discrepancy 
between the minor response to LTB4 in APP and the major unstimulated 
pustulation implies that other chemotactic factors as LTB4 are a 
condition sine qua non for the appearance of the pustules in APP. 
However, it is remotely possible that LTB4 and other lipoxygenase 
products might play a role in the initial phase of a relapse of APP. 
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Mammalian tissues contain a wide range of proteinase inhibitors, many 
of which seem to have specific functions in physiological processes 
such as the coagulation, fibrinolytic or complement pathways.1 
Several of these inhibitors have been demonstrated in skin, a field 
which has been reviewed by Hopsu-Havu.2 
During our previous investigations using elastase as marker enzyme 
for polymorphonuclear leukocytes (PMN)' it was shown that if a neutral 
detergent such as Triton X-100 was employed for enzyme solubilization, 
extracts of normal human skin caused an unacceptably high level of 
inhibition. However, use of an cationic detergent (cetrimide) avoided 
this problem; under the conditions described the inhibition was 
limited to about 10% and was independent of the quantity of elastase 
present in the assay.' 
Surprisingly, we have subsequently observed that psoriatic lesionai 
skin (PL) contains an inhibitor which reacts stochiometrically with 
PMN elastase even in the presence of cetrimide, and which seems not be 
present in healthy skin. Here we report a preliminary characterization 
of this inhibitor. 
MATERIALS AND METHODS 
Materials 
A patient (male, age 71) was selected with a 36-year history of 
chronic plaque psoriasis. A biopsy (approx. 0.3 mm thickness, 1 cm2) 
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was taken from the central region of a typical lesion using a Castro-
viejo keratotome. This was homogenised at 10 mg/ml in a buffer con­
taining 0.3Й cetrimide, 1 mol/1 NaCI and 0.1 mol/1 Tris at a pH of 
8.5. The homogenate was centrifuged (20,000 g, 10 min) to yield a 
clear supernatant ('PL extract'). 
PMN were isolated from the blood of healthy volunteers using stan­
dard procedures.* These were lysed by sonification in cetrimide buffer 
(above) at a concentration of 10^ cells/ml, and the lysate centrifu­
ged. The supernatant ('PMN extract') was used as a crude source of 
leukocyte elastase. 
Elastase assay 
This was a modification of the method described previously', in 
which enzyme activity is determined by the fluorescence of 7-amino-4-
methylcoumarin released from the substrate MeOSuc-Ala-Ala-Pro-Val-N-
methyIcoumarin. 
In brief, the reaction was initiated by the addition of 20 μΐ sub­
strate (250 μΐηοΐ/ΐ in cetrimide buffer) to 20 μΐ of a solution con­
taining PMN extract and PL extract at appropriate dilutions. After 
incubation for 1 h at 370C, the reaction was stopped by the addition 
of 1 ml of carbonate buffer (0.1 mol/1, pH 10.5), and the fluorescence 
determined (excitation = 375 nm, emission = 440 nm). Enzyme activity 
was calculated by reference to a 10~' mol/1 solution of 7-amino-4-
methyIcoumarin. 
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Inhibitor kinetics 
Two sets of experiments was conducted to demonstrate the stochio-
metric nature of the inhibition. In the first, a series of assays was 
carried out using a fixed quantity of PMN extract (equivalent to 500 
cells per assay) and varying the concentration of the added PL extract 
in the range 0-1 mg/ml. In the second set of assays, the quantity of 
PL extract was constant (equivalent to 1 //g PL per assay), and the 
concentration of the added PMN extract varied in the range up to 500 
cells/assay. 
%remaining elastase activity of 500PMN 
100-
i.0 
20 
ι Г^ 
10 ,υς skin 
Fig. 1. Remaining elastase activity of 500 PMN in the 
presence of different concentrations of PL extract. 
- 100 -
Other experiments 
Aliquota of the PL extract (diluted to 0.25 mg/ml) were dialysed 
against cetrimide buffer prior to assay, using a membrane of about 2 
KD cut off, in order to obtain some idea of the molecular weight of 
the inhibitor. In other experiments the PL extract was heated to 100oC 
for varying times up to 30 min prior to assay. 
RESULTS 
The results of the experiments using different concentrations of PL 
extract are shown in Fig. 1, and those using different concentrations 
of PMN extract in Fig. 2. Thesa date make it clear that there is a 
stochiometric relationship between the enzyme and the inhibitor. 
Extrapolation of the linear regions of the graphs to the X-axis indi-
cates the quantitative equivalence between the enzyme activity and the 
inhibitor; both experiments yield a figure of about 3 ^g of PL neutra-
lizing the elastase derived from 500 PMN. 
The dialysis experiments showed that the activity of the PL extract 
was wholly retained by the membrane, indicating a MW > 2000 Daltons. 
The inhibitor seemed remarkably heat-stable, retaining its full acti-
vity after 30 min at 100oC. 
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Fig. 2. Remaining elastase activity in PMN extracts of 
different concentrations in the presence of 1 μq 
lesionai skin. 
DISCUSSION 
This study must obviously be regarded as preliminary, firstly, 
because no attempt has been made to isolate the inhibitor and second­
ly, because a crude PMN lysate was employed rather than a purified 
elastase preparation. However, it is beyond doubt that a protease 
inhibitor is present in extremely high concentrations in psoriatic 
60-
40-
20-
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lesionai skin which is not present in the normal tissue. 
This inhibitor does not correspond to any previously described in 
epidermis, since the latter have been isolated from normal skin. Two 
possibilities exist: firstly, that the observed inhibitor is derived 
from plasma, and reaches the PL because of abnormally increased tissue 
permeability; secondly, that it is synthesized by the local epidermal 
cell population in the lesion. Since we have observed that blood serum 
at a dilution corresponding to the PL extract does not significantly 
inhibit PMN elastase, we are inclined to support the latter view. 
Further research in this field includes the isolation and the com-
plete characterization of the inhibitor (molecular weight, isoelectric 
point, etc.), determination of the range of proteases with which the 
inhibitor interacts and elucidation of the clinical situations in 
which the inhibitor is synthesized by skin. 
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CHAPTER Χ 
GENERAL DISCUSSION AND CONCLUSIONS. 
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METHODS 
Elastase assay 
Chapter II discusses the enzymological method, using elastase as a 
marker enzyme for the quantification of polymorphonuclear leukocytes 
(PMN) in skin infiltrates. 
This method proved to be extremely sensitive. Five PMN, derived from 
human blood, could be traced per assay and the measurements were 
linear up to 1000 PMN per sample. In skin homogenates (containing 2 mg 
skin per ml), the determination of 80 PMN in 20 μΐ of homogenate was 
possible. After the epicutaneous application of a small amount of 2 ng 
of leukotriene B4 (LTB4), on a skin surface of 0.4 cm^, PMN accumula­
tion was detectable. This is far below the detection limit, using his­
tological methods. At least 10 ng of LTB4 was needed topically on an 
area of 0.4 cm' to induce a visible PMN accumulation into the epider­
mis, using conventional histopathology.^ The fluorometric method is 
very specific, since the leukocyte type elastase is not present in any 
other type of human cell. Monocytes contain a small amount of elasta­
se; its properties, however, are totally different from the PMN type 
elastase.' Another advantage of this method is the possibility to 
assess the accumulation of PMN in a whole biopsy in one single measu­
rement. In conventional histology, serial sectioning and investigation 
of many sections is necessary to estimate the intraepidermal penetra­
tion of PMN, especially if PMN occur in limited amounts. 
Nevertheless, a disadvantage of the enzymological method, compared 
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to histological methods, is the lack of information about the topo­
graphy, viz. the relation of PMN to other cells, and to the different 
cell layers of the epidermis. 
The potential of the 'elastase method' are limited by the presence 
of an elastase inhibitor. PMN accumulation can be assessed only when 
the level of the elastase inhibitor is low. Measurements can be cor­
rected for the inhibition when an internal standard is used. This 
includes that the 'elastase method' is not usable in psoriatic lesio­
nai skin, аз a result of high amounts of an elastase inhibitor. 
LTBa application 
To approximate the PMN accumulation in the psoriatic lesion, LTB4 
was applied epicutaneously. This method is described in Chapter III. 
Small amounts of LTB4 already induced a significant and reproducable 
PMN infiltrate. Application of 2 ng LTB4 at an area of 0.4 cm^ resul­
ted, 24 hours later, in measurable PMN exocytosis into the clinically 
normal skin. Using the elastase method, a dose-response relation was 
yielded in the range of 5-500 ng LTB4. 
The advantage of this model is the possibility to study the dynamics 
of PMN accumulation 'in situ' in human skin. We prefer an in vivo 
experiment. Over the past few years, much research has been done on 
the peripheral blood PMN. It should be realized, however, that the 
population of PMN that infiltrate the skin night be a subpopulation 
and might have different properties.-^ 
The effect of antipsoriatic therapies on PMN accumulation in skin 
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can be studied by taking sequential biopsies during treatment. Using 
this approach, it is impossible to differentiate between a direct 
effect of the treatment on PMN behaviour and an indirect effect on the 
PMN, secondary to a therapeutical interference at a totally different 
level. As the model of LTB^-induced PMN accumulation represents a 
clear biological system, a direct interference of therapies with PMN 
behaviour can be studied. 
In the experiments, LTB4 was selected as chemoattractant, since it 
represents an important mediator in the pathogenesis of psoriasis.* 
Psoriatic lesionai skin contains several chemoattractive substances, 
from which LTB4 is probably one of the stongest.·* In the psoriatic 
lesion, the source of LTB4 is not known. Triggering factors might sti-
mulate keratinocytes to produce LTB4. Subsequently PMN accumulate, 
which release LTB4, resulting in a vicious circle. 
Single applications of LTB4 on skin results in macroscopic changes 
depending on the dose of LTB4, the time interval between the LTB4 
application and examination of the test sites. 36 Hours following LTB4 
application, we observed macroscopic skin changes only on one patient, 
using a dose of 10 ng LTB4 on 0.4 cm^ skin, although skin changes 
induced by LTB4 have been reported and consist of erythema and papu-
les, followed by fine, powder-like scaling and occasionally vesicular 
or pustular reactions.' 
The LTB4-induced PMN accumulation as a model diverges from the situ-
ation in psoriasis in some respects. Classical psoriatic lesions, 
following LTB4 application, were not observed and have not been repor-
ted by other researchers. In addition, the histological features of 
the intraepidermal micropustules following LTB4 application, did not 
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correspond with the typical spongiform aspect of the pustules in the 
psoriatic lesion. In the psoriatic lesion a periodic discharge of PMN 
occurs, whereas in our model PMN accumulate in one single wave. More-
over, we have to take into account that LTB4, besides PMN, attracts 
lymphocytes (IS), monocytes (3%) and eosinophils (.2%) as well. 
GENERAL CONCLUSIONS 
Pathogenetic aspects 
The LTB4-induced PMN accumulation was slightly but significantly 
decreased in the clinically uninvolved skin of untreated psoriatic 
patients compared to healthy controls (Chapter III). 
Chapters VI and VII describe the situation in the psoriatic lesion. 
In 41% of stable psoriatic lesions, PMN accumulation was not observed, 
using histological methods. In the psoriatic lesion it was not possi-
ble to induce microabscesses using high amounts of LTB4 (100 ng at 0.4 
cm^). In psoriasis pustulosa the spontaneous accumulation of PMN was 
limited to the clinically involved skin and the LTB4-induced PMN 
infiltration was markedly decreased in lesionai, pre-lesionai and 
post-lesional skin (Chapter VIII). 
These findings all lead to the same conclusion: The LTBa-induced PMN 
accumulation is disturbed in psoriasis. A kind of 'habituation' to 
LTB4 was shown in the clinically uninvolved skin of psoriatic patients 
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with a crescendo to lesionai skin and clinically involved and uninvol-
ved skin of pustular psoriasis. 
The decreased responsiveness to LTB4 appears to be inversely related 
to LTB4 formation. LTB4 production has been reported to be slightly 
increased in the uninvolved psoriatic skin, compared to skin of heal-
thy volunteers.8 In lesionai psoriatic skin the production of LTB4 
is markedly increased.^ These data indicate that LTB4 is probably 
the initiating step in a switch-on system, essential in the homeosta-
tic control of the skin. 
A balance seems to develop between triggering factors and the 
attempt to normalize homeostasis (Table I). Depending on this balance, 
lesions might spread, disappear or stabilize. Wong et al. found a 
tolerance following multiple applications of LTB4 in healthy skin, 
which confirms this theory.9 
lesionai skin clinically uninvolved 
skin 
LTB4 production 
LTB4 induc-ed PMN 
accumulation 
PMN accumulation 
Table I. LTB4 production and PMN accumulation in 
psoriatic patients. 
m Î 
11 
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Therapeutic aspects 
Methotrexate, in therapeutical doses inhibited the LTB^-induced 
Chemotaxis into skin. Clinical effectivity correlated with the inhibi­
tory effect on the 'in situ' Chemotaxis, indicating that this inter­
ference might be closely related to the antipsoriatic target of metho­
trexate. In all psoriatic patients, treated with etretinate, an inver­
se relation was observed between the dosage of etretinate and the 
LTB4-induced, 'in situ' Chemotaxis into skin (Chapters IV and V). 
From these data we may conclude that the systemic antipsoriatic 
therapies interfere with the LTBu-induced PMN accumulation in the sane 
direction as the so-called 'habituation' to ΙΤΒ^. The exact working-
mechanism of these therapies is unknown; they might reinforce the 
'habituation' process or have a direct effect on circulating PMN. For 
methotrexate, direct interference with PMN functions have been descri­
bed. For etretinate this situation is less clear. 
Explanations for the habituation to LTB^ 
At this stage we can only speculate on the mechanism involved in the 
'habituation' process following topical application of LTB4. Several 
investigators have suggested the presence of a regulating, inhibiting 
factor in psoriasis. Dubertret et al. proposed the production of an 
inhibitor by psoriatic skin which resulted in a decreased chemotactic 
activity of neutrophils.'^ Czarnetzki et al. proposed the presence 
of substances in psoriatic scales that work and chemotactic, and inhi-
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bit PMN Chemotaxis.11 Stankler suggested the presence of a homeosta-
tic substance in the circulation of recovering patients, responsible 
for the inhibition of the Koebner phenomenon.12 Tigalonowa et al. 
reported that psoriatic serum of patients with stable psoriasis sup­
presses PMN migration.1^ 
Several explanations for the 'habituation' to LTB4 exposure seem 
possible: (1) LTB4 is metabolized quickly by PMN, via ω-oxidation into 
20-hydroxy LTB4 and 20-carboxy LTB4, which are less chemotactic than 
LTB4.14>1!>i1i>>1"7>1f3 Ljtfy application might induce the enzyme, neces­
sary for this inactivation. Such a mechanism is comparable with the 
induction of the cytochrome P450 dependent microsomal enzyme, aryl 
hydrocarbon hydroxylase, that metabolizes several drugs, and has a 
greater responsiveness to polycyclic aromatic hydrocarbon in psoriatic 
skin, compared to healthy controls.1" 
(II) The inhibition of the chemotactic function of LTB4 might be 
caused by an occupation of active sites of LT84. This theory is very 
likely, as LTB4 is still measurable in the chronic psoriatic plaque. 
(III) PMN migration is directed towards a gradient of Chemotaxis. In 
psoriatic patients, large amounts of LTB4 are present, regularly 
spread throughout the body, without the presence of a concentration-
gradient. In this situation PMN will not migrate. 
(iv) Another reason for the extinction of the continuous LTB^-indu-
ced PMN accumulation may be a depletion of one of the mediators of the 
cascade that leads to PMN accumulation. 
(v) Some investigators describe the presence of LTB4 receptors on 
PMN.20 Colditz and Movat showed a desensization of PMN inflammatory 
response to intracutaneous injection of different chemotaxins and 
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proved that LTB^ is not a final common mediator of PMN infiltration. 
They suggested a down regulation of a receptor-mechanism for chemota-
xins on endothelial cells that facilitates PMN extravasation in acute 
inflantmatory lesions.21 These receptors (localized on PMN or on 
endothelial cells) might be occupied by an unknown substance, probably 
by LTB4 itself. An inactivated or degradation product of LTB4 might 
antagonize the function of LTB4 m this way. 
(vi) It is suggested that the enhanced activity in psoriasis is 
caused by circulating factors, called Opsonines (complement factors 
and immunoglobulins).22 д change in the level of these Opsonines 
might interfere with PMN activity. 
On the basis of our experimental rp°ijlts we suggest an alternative 
regulation mechanism for the 'habituation' to LTB^-induced PMN inva­
sion: the enzyme elastase and inhibitors of this enzyme. Elastase 
facilitates the penetration of PMN into tissue.23 Inhibition of 
elastase activity will prevent PMN elastase from degrading the base­
ment-membrane of the skin and will result in a restraining influence 
on the penetration of PMN into tissue. The elastase inhibitor may be 
an inbuilt protection against LTB^-induced PMN accumulation and their 
LTB4 production. This inhibitor might be part of the on-off switch 
mechanism induced by LTB4, by LTB4-induced PMN or by their degrada­
tion-products. 
We demonstrated the presence of elastase inhibitors in human skin, 
which could be subdivided into an inhibitor characteristic of the 
psoriatic lesion (Chapter IX) and one or more inhibitors present in 
uninvolved psoriatic skin and skin of healthy controls. 
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Both inhibitors have different properties. The latter did not in-
crease during 36 hours following LTB4 application, nor was there any 
difference in the degree of inhibition between the psoriatic group 
compared to controls. Addition of skin at a concentration of 2 mg per 
ml to a PMN concentrate resulted in an inhibition of about IOS of the 
elastase activity and was independent of the amount of PMN. Sulphated 
glycosaminoglycans are said to cause this inhibition.24 
The inhibitor, characteristic of the psoriatic lesion, was present 
in very large amounts in the lesion and negligible in uninvolved 
skin. In addition, it was a stochiometnc type inhibitor, in contrast 
to the inhibitor in the clinically uninvolved skin. 
It is not known whether the elastase inhibitors are produced by the 
keratinocytes, the infiltrated cells, or are produced elswhere and 
subsequently accumulate into the skin. As serum and skin, containing 
LTB^-induced PMN infiltrates, contain negligible levels of this inhi-
bitor, the keratinocyte is the most likely source for this inhibitor. 
The production might be triggered by a mediator of inflammation. In 
this respect, 15-hydroxy-eicosatetraenoic acid (15-HETE), specifically 
inhibiting LTB^-induced PMN Chemotaxis, can be regarded as a possible 
factor.25 The explanation for the scarce PMN exocytosis in the 
stable, chronic psoriatic lesion that breaks through the inhibitor 
might be due to a circadian rhythm of the production of the inhibitor 
that incidentally permits the chemotactic response of PMN to high 
levels of LTB4.26 
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FUTURE PROSPECTS 
Current antipsoriatic therapies have a broad working spectrum on 
several cell activities in humans, resulting in a range of effects, 
also including side-effects. Therefore, research into new, more speci-
fic therapeutic approaches seems necessary. 
Antipsoriatic therapies might work through the induction of the 
habituation mechanism for PMN Chemotaxis. These treatments might 
induce a specific receptor antagonist, mark LTB4 from the acceptor 
sites, interfere with an intermediate, or inactivate leukotnenes. 
With regard to this it is of interest that lonapalene, a 5-lipoxyge-
nase inhibitor, which has an antipsoriatic effect, inhibits the pro-
duction of leukotnenes and results in an increase of 15-HETE as 
well.2' Experiments have revealed an inhibition of LTB^-induced PMN 
accumulation by 15-HETE." 
LTB4 has proved to play an important role both in the initiation of 
PMN accumulation and in the triggering of the consolidation mechanism 
in psoriasis. The most obvious way to treat psoriasis seems to be the 
application of medicaments that suppress leukotnene production. An 
alternative therapy might be the reverse treatment: LTB4 and other 
inflammatory eicosanoids applied topically in increasing concentra-
tions, starting with very low amounts, may stimulate the habituation 
that protects the skin against LTB^-induced PMN invasion. 
A striking similarity seems to exist between the habituation of PMN 
to LTB4 and the working mechanism of UVB therapy employed in chronic 
polymorphic light dermatosis and in psoriasis. UVB radiation might 
work via the stimulation of the arachidonic acid cascade. Increased 
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levels of prostaglandins and leukotnenes in skin have been measured 
following UVB radiation, which might induce a habituation mechanism 
that protects against further inflammation, resulting in the well-
known improvement on this therapy.28 
The third possibility for intervention might be the use of elastase 
inhibitors. Exact characterization of the elastase inhibitor present 
in psoriatic lesionai skin, might open new perspectives. 
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SUMMARY 
THE LEUKOTRIENE B4-INDUCED ACCUMULATION OF POLYMORPHONUCLEAR LEUKO­
CYTES IN PSORIATIC SKIN 
The thesis attempts to provide insight into the role of polymorpho­
nuclear leukocytes in the initiation, maintenance and therapeutically 
induced regression of the psoriatic lesion. 
In the introduction (chapter I) the epidemiologic, genetic, clini­
cal, histopathologic and therapeutical aspects of psoriasis are revie­
wed. Besides, an overview is given of the research concerning the 
pathogenesis of psoriasis, carried out over the past 15 years. 
Chapter II describes a method that quantifies polymorphonuclear leu­
kocytes in skin infiltrates, using elastase as a marker enzyme. Elas-
tase was determined by the fluorescence of 7-amino-4-methylcoumarin, 
released from the substrate MeOSuc-Ala-Ala-Pro-Val-N-Methylcoumarin. 
The mean activity was 0.57 ± 0.08 pmol of 7-amino-4-methylcoumarin per 
hour per polymorphonuclear leukocyte. 
In chapter III the response of polymorphonuclear leukocytes to topi­
cal leukotriene Вц in the uninvolved skin of psoriatic patients is 
compared to the response in skin of healthy controls. The 'in situ' 
Chemotaxis into skin of psoriatic patients proved to be slightly de­
creased. 
- 121 -
Chapter IV deals with the effects of methotrexate on the 'in situ' 
Chemotaxis of polymorphonuclear leukocytes into the psoriatic skin 
induced by topical leukotriene B4. Methotrexate in therapeutical doses 
proved to inhibit the accumulation of polymorphonuclear leukocytes in 
psoriatic patients who improved during this treatment. A recovery of 
the Chemotaxis of polymorphonuclear leukocytes was seen during the 
days in which no methotrexate was ingested. The Chemotaxis of poly-
morphonuclear leukocytes was not influenced by methotrexate in pa-
tients who were in relapse despite the treatment with this substance. 
In chapter V the inhibitory effect of etretinate on the Chemotaxis 
of polymorphonuclear leukocytes into skin is demonstrated. The inhibi-
tory influence of etretinate on the in vivo accumulation of poly-
morphonuclear leukocytes showed a dose-reponse relation. 
In chapter VI the intraepidermal accumulation of polymorphonuclear 
leukocytes into the chronic, stable plaque phase of psoriasis is mea-
sured. Intraepidermal polymorphonuclear leukocytes were seen in 41S of 
the lesions. In 10 out of 29 lesions, Munro microabscesses were visi-
ble and in 3 out of 29 lesions micropustules of Kogoi were detected. 
Both features are said to be characteristic of psoriasis. Sporadic 
penetration of polymorphonuclear leukocytes in the epidermis was 
observed in 2 out of 29 lesions. The presence of polymorphonuclear 
leukocytes is characteristic for acute lesions, however, in chronic 
lesions they are seen less frequent. 
Chapter VII deals with the leukotriene B^-induced accumulation of 
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polymorphonuclear leukocytes into the epidermis; tested in the invol-
ved and uninvolved skin of patients with chronic stable plaque psoria-
sis. Following the application of 100 ng leukotriene B4 to the psoria-
tic lesionai skin, absolutely no accumulation of polymorphonuclear 
leukocytes was detected, as opposed to the uninvolved psoriatic skin. 
In chapter VIII the intraepidermal accumulation of polymorphonuclear 
leukocytes in the different zones of the skin of a patient suffering 
from annular pustular psoriasis is assessed. The leukotriene B^-indu-
ced accumulation of polymorphonuclear leukocytes proved to be decrea-
sed in pre-lesionai, lesionai and post-lesional skin, compared to the 
uninvolved skin of patients with chronic plaque type psoriasis. 
Chapter IX reports on a preliminary characterization of an inhibitor 
of polymorphonuclear leukocyte elastase, which is present in psoriatic 
lesionai skin. The inhibitor reacted stochiometrically with polymor-
phonuclear leukocyte elastase and was nearly absent in uninvolved 
psoriatic skin. The inhibitor was heat stable and had a molecular 
weight > 2000 Daltons. 
In chapter X the advantages and disadvantages of the methods used in 
the experiments are reviewed. From the results of the experiments, the 
following conclusion can be drawn: the leukotriene B4-induced accumu-
lation of polymorphonuclear leukocytes into skin is disturbed in pso-
riasis. A kind of 'habituation' to leukotriene B4 was shown in the 
clinically uninvolved skin of psoriatic patients. In lesionai skin in 
chronic stable plaque psoriasis and the whole skin of a patient with 
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pustular psoriasis this habituation was highly pronounced. 
In addition, the therapeutic aspects are discussed. The systemic 
antipsoriatic therapies interfere with the leukotriene Вд-induced 
accumulation of polymorphonuclear leukocytes in the same direction as 
the so-called 'habituation' to leukotriene B4. Some explanations for 
this habituation-mechanism are suggested and about the therapeutic 
consequenses of this mechanism is speculated. 
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SAMENVATTING 
DE DOOR LEUKOTRIENE B4-GEÏNDUCEERDE ACCUMULATIE VAN POLYMORPHKERNIGE 
GRANULOCYTEN IN DE HUID BIJ PSORIASIS 
De doelstelling van dit proefschrift is een beter inzicht te ver-
krijgen in de rol van de polymorphkernige granulocyten bij het ont-
staan en onderhouden van de psoriasis laesie en bij de door therapeu-
tische interferentie verkregen verbetering van de huidafwijkingen. 
De introductie (hoofdstuk I) geeft een overzicht over de epidemiolo-
gische, genetische, klinische en histopathologische aspecten van pso-
riasis. Tevens wordt een samenvatting gegeven van de onderzoekingen 
betreffende de Pathogenese van psoriasis, verricht in de afgelopen 15 
jaar. 
In hoofdstuk II wordt een methode beschreven voor het quanti ficeren 
van polymorphkernige granulocyten in huidinfiltraten. Hierbij wordt 
gebruik gemaakt van een marker enzym, elastase. Elastase katalyseert 
de omzetting van MeOSuc-Ala-Ala-Pro-Val-N-Methylcoumann waarbij 7-
amino-4-methylcoumarin vrijkomt. De snelheid waarmee 7-amino-4-methyl-
coumann gevormd wordt is aldus een maat voor de hoeveelheid elastase 
dat aanwezig is in het reactie mengsel. De gemiddelde activiteit per 
polymorphkernige granulocyt was 0,57 ± 0,08 pmol 7-amino-4-methylcou-
mann per uur. 
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In hoofdstuk III wordt de reactie van polymorphkernige granulocyten 
op de locale applicatie van leukotriene B4 vergeleken in klinisch nor-
male huid van psoriasis patiënten met de reactie in huid van gezonde 
controle personen. De 'in situ' Chemotaxis in huid van psoriasis 
patiënten bleek licht verlaagd te zijn. 
Hoofdstuk IV behandelt het effect van methotrexaat op de 'in situ' 
Chemotaxis van polymorphkernige granulocyten in de huid van psoriasis 
patiënten, geïnduceerd door locale applicatie van leukotriene B4. 
Methotrexaat bleek in therapeutische doseringen de accumulatie van 
polymorphkernige granulocyten te remmen bij psoriasis patiënten welke 
een duidelijke verbetering vertoonden gedurende behandeling met metho-
trexaat. De Chemotaxis van polymorphkernige granulocyten herstelde 
gedurende de dagen waarop geen methotrexaat werd ingenomen. Bij de 
patiënten die klinisch niet verbeterden, ondanks behandeling met 
methotrexaat, werd geen verandering in de Chemotaxis van de polymorph-
kernige granulocyten gezien. 
Hoofdstuk V beschrijft het inhiberende effect van etretinate op de 
door leukotriene B4 geïnduceerde ophoping van polymorphkernige granu-
locyten in de huid. De mate van inhibitie is afhankelijk van de dosis 
etretinate. 
In hoofdstuk VI wordt de intraepidermale accumulatie van polymorph-
kernige granulocyten in de chronische stabiele plaque fase van psoria-
sis gequantificeerd. In slechts 41" van de laesies werden polymorph-
kernige granulocyten gezien. In 10 van de 29 bestudeerde laesies waren 
- 126 -
microabcessen van Munro en in 3 van de 29 laesies waren micropustels 
van Kogoi zichtbaar. Beide verschijnselen zouden karakteristiek zijn 
voor psoriasis. In 2 van de 29 laesies werden intraepidermaal enkele 
sporadische polymorphkernige granulocyten gezien. Hoewel de aanwezig-
heid van polymorphkernige granulocyten in acute laesies op de voor-
grond staat, worden ze in de chronische fase daarentegen beduidend 
minder vaak gezien. 
Hoofdstuk VII beschrijft de door leukotnene B4 geïnduceerde accumu-
latie van polymorphkernige granulocyten in de laesie en in de klinisch 
normale huid van patiënten met chronisch stabiele plaque psoriasis. 
Door middel van de applicatie van 100 ng leukotnene B4 op de psoria-
sis laesie kon geen intraepidermale infiltratie met polymorphkernige 
granulocyten geïnduceerd worden, in tegenstelling tot de klinisch nor-
male huid. 
In hoofdstuk VIII wordt de intraepidermale ophoping van polymorph-
kernige granulocyten bepaald in de verschillende zones van de huid bij 
een patiënt met annulaire psoriasis pustulosa. De door leukotnene B4 
geïnduceerde vorming van micropustels bleek afgenomen te zijn in de 
pre-laesionale, laesionale en post-laesionale huid, vergeleken met de 
klinisch normale huid van patiënten met chronisch stabiele plaque pso-
riasis. 
Hoofdstuk IX geeft een eerste aanzet in de karaktenzenng van een 
inhibitor van leukocyten elastase welke in grote hoeveelheden voorkomt 
in de psoriasis laesie. De inhibitor reageerde stochiometnsch met 
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leukocyten elastase en was nauwelijks aantoonbaar in de klinisch nor-
male huid van psoriasis patiënten. De inhibitor was hitte stabiel en 
had een molecuulgewicht > 2000 Daltons. 
In hoofdstuk X worden de voor- en de nadelen van de in de experimen-
ten gebruikte methoden besproken. De resultaten van de onderzoekingen 
leiden tot de volgende eenduidige conclusie: de leukotriene B4 geïndu-
ceerde accumulatie van polymorphkernige granulocyten in de huid is 
verstoord bij psoriasis. Een soort 'gewenning' voor leukotriene B4 
treedt op in de klinisch normale huid van psoriasis patiënten. In de 
laesie bij chronisch stabiele plaque psoriasis en in de gehele huid 
bij psoriasis pustulosa was deze 'gewenning' zeer uitgesproken. 
Vervolgens worden de therapeutische aspecten besproken. De systemi-
sche behandelingen voor psoriasis interfereren met de leukotriene B4-
geïnduceerde accumulatie van polymorphkernige granulocyten in dezelfde 
richting als de zogenaamde 'gewenning' aan leukotriene B4. 
De mogelijke verklaringen van dit gewennings-fenomeen worden bespro-
ken en over de therapeutische consequenties van dit mechanisme wordt 
gespeculeerd. 
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STELLINGEN 
1. Zeer nauwkeurige quantificenng van polymorphkernige granulocyten 
in de huid is mogelijk door bepaling van de activiteit van het 
enzym elastase. 
2. Het ontbreken van polymorphkernige granulocyten bij histopatholo-
gisch onderzoek van een chronische huidlaesie sluit de diagnose 
psoriasis niet uit. 
3. In de normaal uitziende, maar nog meer in de klinisch aangedane 
huid van patiënten met psoriasis is de accumulatie van polymorph-
kernige granulocyten na epicutaan appliceren van leukotnene B4 
lager dan bij proefpersonen zonder psoriasis. 
4. De discrepantie tussen de overmaat aan leukotnenen en een rela-
tief gering aantal polymorphkernige granulocyten in de chronische 
psonasislaesie kan gedeeltelijk worden verklaard door het voor-
komen van een elastase-inhibitor. 
5. Bij de vroegdiagnostiek van mycosis fungoïdes wordt door middel 
van infiltraatanalyse met behulp van monoclonale antilichamen geen 
aanvullende informatie verkregen. 
6. Het voorkomen van lupus anticoagulant bij lupus erythematodes is 
geassocieerd met een verhoogde kans op mislukte zwangerschap. Het 
gunstige effect van corticosteroiden op het verloop van de 
zwangerschap bij deze patiënten dient te worden onderzocht. 
(R.H.W.M. Derksen e.a., Arthritis. Rheum. 1986; 29: 695) 
7. De drempelverhoging van de poliklinieken voor geslachtsziekten zal 
de geslachtsziektenbestrijding niet ten goede komen. 
8. Volgens de huidige inzichten moet röntgenbehandeling van benigne 
dermatosen als obsoleet worden beschouwd. 
9. Het nastreven van een cosmetisch effect op korte termijn door 
middel van kunstmatige lichtbronnen, betekent een nadelig effect 
op lange termijn. 
10. Onderzoek naar de behandeling van het gemetastaseerde prostaat-
carcinoom dient zich te richten op de hormoonongevoelige kanker-
cellen. 
11. Eenmaal daags monotherapie met het derde generatie Cephalosporine 
ceftriaxon is eenvoudig, minstens zo effectief en tijd- en kosten-
besparend in vergelijking met het geven van de combinatie van 
gentamicine en Cefuroxim bij de initiële behandeling van ernstige 
bacteriële infecties. 
12. Bloedarmoede door sportbeoefening moet gezien worden als een 
onschuldige bijwerking van een gezonde hobby. 
13. Periodieke controle van prostituees op geslachtsziekten kan leiden 
tot een onverantwoord gevoel van veiligheid. 
Stellingen behorend bij het proefschrift 'The leukotriene B^induced 
accumulation of polymorphonuclear leukocytes in psoriatic skin'. 
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